Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

153 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Acquired von Willebrand syndrome: from pathophysiology to management.
Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Veyradier A, et al. Thromb Haemost. 2000 Aug;84(2):175-82. Thromb Haemost. 2000. PMID: 10959686 Review. No abstract available.
Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature.
Elessa D, Talbot A, Lombion N, Harel S, Galicier L, Veyradier A, Joly B, Andreoli A, Rigaudeau S, Azoulay É, Coppo P, Royer B, Arnulf B. Elessa D, et al. Among authors: veyradier a. Br J Haematol. 2020 Jan;188(2):338-340. doi: 10.1111/bjh.16333. Epub 2019 Dec 15. Br J Haematol. 2020. PMID: 31840243 No abstract available.
Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.
Prevel R, Roubaud-Baudron C, Gourlain S, Jamme M, Peres K, Benhamou Y, Galicier L, Azoulay E, Poullin P, Provôt F, Maury E, Presne C, Hamidou M, Saheb S, Wynckel A, Servais A, Girault S, Delmas Y, Chatelet V, Augusto JF, Mousson C, Perez P, Halimi JM, Kanouni T, Lautrette A, Charvet-Rumpler A, Deligny C, Chauveau D, Veyradier A, Coppo P. Prevel R, et al. Blood. 2019 Dec 12;134(24):2209-2217. doi: 10.1182/blood.2019000748. Blood. 2019. PMID: 31530564
Compared with a non-iTTP geriatric population, older survivors showed an increased long-term mortality (hazard ratio = 3.44; P < .001). ...

Compared with a non-iTTP geriatric population, older survivors showed an increased long-term mortality (hazard ratio = 3.44; P < .

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.
Graça NAG, Ercig B, Velásquez Pereira LC, Kangro K, Kaijen P, Nicolaes GAF, Veyradier A, Coppo P, Vanhoorelbeke K, Männik A, Voorberg J. Graça NAG, et al. Haematologica. 2019 Nov 21:haematol.2019.226068. doi: 10.3324/haematol.2019.226068. Online ahead of print. Haematologica. 2019. PMID: 31753929
In this study we present a detailed contribution of each residue in this epitope for autoantibody binding. Different panels of mutations were introduced here to create a large collection of full-length ADAMTS13 variants comprising conservative (Y←→F), semi-conservat …
In this study we present a detailed contribution of each residue in this epitope for autoantibody binding. Different panels of mutati …
Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
le Besnerais M, Veyradier A, Benhamou Y, Coppo P. le Besnerais M, et al. Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134. doi: 10.1080/14712598.2019.1650908. Epub 2019 Aug 5. Expert Opin Biol Ther. 2019. PMID: 31359806 Review.
Expert opinion: Caplacizumab is a new drug with a complementary mechanism of action with respect to the standard available therapeutics. It demonstrated efficacy in clinical trials through a faster platelet count normalization and protection of patients from …
Expert opinion: Caplacizumab is a new drug with a complementary mechanism of action with respect to the standard available the …
Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura.
Garraud O, Malot S, Herbrecht R, Ojeda-Uribe M, Lin JS, Veyradier A, Payrat JM, Liu K, Corash L, Coppo P. Garraud O, et al. Transfus Apher Sci. 2019 Dec;58(6):102665. doi: 10.1016/j.transci.2019.10.007. Epub 2019 Nov 5. Transfus Apher Sci. 2019. PMID: 31740165 Clinical Trial.
METHODS: We conducted a retrospective review of iTTP cases prospectively reported to the French national registry (2010-2013). ...
METHODS: We conducted a retrospective review of iTTP cases prospectively reported to the French national registry (2010-2013). ...
Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.
Azoulay E, Bauer PR, Mariotte E, Russell L, Knoebl P, Martin-Loeches I, Pène F, Puxty K, Povoa P, Barratt-Due A, Garnacho-Montero J, Wendon J, Munshi L, Benoit D, von Bergwelt-Baildon M, Maggiorini M, Coppo P, Cataland S, Veyradier A, Van de Louw A; Nine-i Investigators. Azoulay E, et al. Intensive Care Med. 2019 Nov;45(11):1518-1539. doi: 10.1007/s00134-019-05736-5. Epub 2019 Oct 7. Intensive Care Med. 2019. PMID: 31588978
This expert statement is timely given the recent advances in the treatment of TTP, such as the use of rituximab and of the recently licensed drug caplacizumab, whose benefits will be maximized if the other components of the management strategy follow a standardized pattern …
This expert statement is timely given the recent advances in the treatment of TTP, such as the use of rituximab and of the recently licensed …
Correction to: Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.
Azoulay E, Bauer PR, Mariotte E, Russell L, Knoebl P, Martin-Loeches I, Pène F, Puxty K, Povoa P, Barratt-Due A, Garnacho-Montero J, Wendon J, Munshi L, Benoit D, von Bergwelt-Baildon M, Maggiorini M, Coppo P, Cataland S, Veyradier A, Van de Louw A; Nine-i Investigators. Azoulay E, et al. Among authors: veyradier a. Intensive Care Med. 2020 Mar;46(3):570-571. doi: 10.1007/s00134-019-05904-7. Intensive Care Med. 2020. PMID: 31965263
Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.
Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Fressinaud E, et al. Blood. 1998 Feb 15;91(4):1325-31. Blood. 1998. PMID: 9454763
Whole citrated blood is aspirated through a capillary to the central aperture of a membrane coated with collagen and with a platelet agonist (either epinephrine or adenosine diphosphate [ADP]). The time required to obtain occlusion of the aperture by a
Whole citrated blood is aspirated through a capillary to the central aperture of a membrane coated with collagen and with a
Laboratory diagnosis of von Willebrand disease.
Veyradier A, Fressinaud E, Meyer D. Veyradier A, et al. Int J Clin Lab Res. 1998;28(4):201-10. doi: 10.1007/s005990050046. Int J Clin Lab Res. 1998. PMID: 9879492 Review.
Among the latter, a decreased von Willebrand factor ristocetin cofactor activity/von Willebrand factor antigen ratio is in favor of the three subtypes (2A, 2M, and 2B) defined by an abnormal interaction between von Willebrand factor and platelet glycoprotein Ib, whereas …
Among the latter, a decreased von Willebrand factor ristocetin cofactor activity/von Willebrand factor antigen ratio is in favor of t …
153 results
Jump to page
Feedback